Cathryn Rankin1, Adetunji T Toriola2, Cornelia M Ulrich3,4,5, Karen W Makar5, Özge Altug-Teber3,4, Jacqueline K Benedetti1, Rebecca S Holmes6, Stephen R Smalley7, Charles D Blanke6, Heinz-Josef Lenz8. 1. Southwest Oncology Group Statistical Center, Seattle, WA. 2. Department of Surgery, Division of Public Health Sciences and Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO. 3. Division of Preventive Oncology, National Center for Tumor Diseases, Heidelberg, Germany. 4. German Cancer Research Center (DKFZ) and German Consortium for Translational Cancer Research (DKTK), Heidelberg, Germany. 5. Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA. 6. Oregon Health & Science University, Portland, OR. 7. Olathe Regional Oncology Center, Olathe, KS. 8. University of Southern California, Los Angeles, CA.
Abstract
BACKGROUND:Recurrence and toxicity occur commonly among patients with rectal cancer who are treated with5-fluorouracil (5-FU). The authors hypothesized that genetic variation in folate-metabolizing genes could play a role in interindividual variability. The objective of the current study was to evaluate the associations between genetic variants in folate-metabolizing genes and clinical outcomes among patients with rectal cancer treated with5-FU. METHODS: The authors investigated 8 functionally significant polymorphisms in 6 genes (methylenetetrahydrofolate reductase [MTHFR] [C677T, A1298C], SLC19A1 [G80A], SHMT1 [C1420T], dihydrofolate reductase [DHFR] [Del19bp], TS 1494del,and TSER) involved in folate metabolism in 745 patients with TNM stage II or III rectal cancer enrolled in a phase 3 adjuvant clinical trial of 3 regimens of5-FU and radiotherapy (INT-0144 and SWOG 9304). RESULTS: There were no statistically significant associations noted between polymorphisms in any of the genes and overall survival, disease-free survival (DFS), and toxicity in the overall analyses. Nevertheless, there was a trend toward worse DFS among patients with the variant allele of MTHFR C677T compared with wild-type, particularly in treatment arm 2, in which patients with the MTHFR C677T TT genotype had worse overall survival (hazards ratio, 1.76; 95% confidence interval, 1.06-2.93 [P = .03]) and DFS (hazards ratio, 1.84; 95% confidence interval, 1.12-3.03 [P = .02]) compared with those with homozygous wild-type. In addition, there was a trend toward reduced hematological toxicity among patients with variants of SLC19A1 G80A in treatment arm 1 (P for trend, .06) and reduced esophagitis/stomatitis noted among patients with variants of TSER in treatment arm 3 (P for trend, .06). CONCLUSIONS: Genetic variability in folate-metabolizing enzymes was found to be associated only to a limited degree with clinical outcomes among patients with rectal cancer treated with5-FU.
RCT Entities:
BACKGROUND: Recurrence and toxicity occur commonly among patients with rectal cancer who are treated with 5-fluorouracil (5-FU). The authors hypothesized that genetic variation in folate-metabolizing genes could play a role in interindividual variability. The objective of the current study was to evaluate the associations between genetic variants in folate-metabolizing genes and clinical outcomes among patients with rectal cancer treated with 5-FU. METHODS: The authors investigated 8 functionally significant polymorphisms in 6 genes (methylenetetrahydrofolate reductase [MTHFR] [C677T, A1298C], SLC19A1 [G80A], SHMT1 [C1420T], dihydrofolate reductase [DHFR] [Del19bp], TS 1494del,and TSER) involved in folate metabolism in 745 patients with TNM stage II or III rectal cancer enrolled in a phase 3 adjuvant clinical trial of 3 regimens of 5-FU and radiotherapy (INT-0144 and SWOG 9304). RESULTS: There were no statistically significant associations noted between polymorphisms in any of the genes and overall survival, disease-free survival (DFS), and toxicity in the overall analyses. Nevertheless, there was a trend toward worse DFS among patients with the variant allele of MTHFRC677T compared with wild-type, particularly in treatment arm 2, in which patients with the MTHFRC677T TT genotype had worse overall survival (hazards ratio, 1.76; 95% confidence interval, 1.06-2.93 [P = .03]) and DFS (hazards ratio, 1.84; 95% confidence interval, 1.12-3.03 [P = .02]) compared with those with homozygous wild-type. In addition, there was a trend toward reduced hematological toxicity among patients with variants of SLC19A1G80A in treatment arm 1 (P for trend, .06) and reduced esophagitis/stomatitis noted among patients with variants of TSER in treatment arm 3 (P for trend, .06). CONCLUSIONS: Genetic variability in folate-metabolizing enzymes was found to be associated only to a limited degree with clinical outcomes among patients with rectal cancer treated with 5-FU.
Authors: K Robien; M M Schubert; T Chay; J Bigler; R Storb; Y Yasui; J D Potter; C M Ulrich Journal: Bone Marrow Transplant Date: 2006-04 Impact factor: 5.483
Authors: Stephen R Smalley; Jacqueline K Benedetti; Stephen K Williamson; John M Robertson; Norman C Estes; Tracy Maher; Barbara Fisher; Tyvin A Rich; James A Martenson; John W Kugler; Al B Benson; Daniel G Haller; Robert J Mayer; James N Atkins; Christine Cripps; John Pedersen; Phillip O Periman; Michael S Tanaka; Cynthia G Leichman; John S Macdonald Journal: J Clin Oncol Date: 2006-08-01 Impact factor: 44.544
Authors: Eva Dreussi; Erika Cecchin; Jerry Polesel; Vincenzo Canzonieri; Marco Agostini; Caterina Boso; Claudio Belluco; Angela Buonadonna; Sara Lonardi; Francesca Bergamo; Sara Gagno; Elena De Mattia; Salvatore Pucciarelli; Antonino De Paoli; Giuseppe Toffoli Journal: Int J Mol Sci Date: 2016-09-05 Impact factor: 5.923
Authors: Jennifer Ose; Akke Botma; Yesilda Balavarca; Katharina Buck; Dominique Scherer; Nina Habermann; Jolantha Beyerle; Katrin Pfütze; Petra Seibold; Elisabeth J Kap; Axel Benner; Lina Jansen; Katja Butterbach; Michael Hoffmeister; Hermann Brenner; Alexis Ulrich; Martin Schneider; Jenny Chang-Claude; Barbara Burwinkel; Cornelia M Ulrich Journal: Cancer Med Date: 2018-05-29 Impact factor: 4.452
Authors: Eva Dreussi; Salvatore Pucciarelli; Antonino De Paoli; Jerry Polesel; Vincenzo Canzonieri; Marco Agostini; Maria Luisa Friso; Claudio Belluco; Angela Buonadonna; Sara Lonardi; Chiara Zanusso; Elena De Mattia; Giuseppe Toffoli; Erika Cecchin Journal: Oncotarget Date: 2016-04-12